CENTOGENE
THE RARE DISEASE COMPANY

Non-invasive Prenatal Testing

CentoNIPT®

Expertise You Can Trust



CentoNIPT® offers genetic, Non-invasive Prenatal Testing (NIPT) to screen for the most common fetal chromosomal abnormalities (Trisomies 21, 18, or 13 and optionally sex chromosome aneuploidies). Optionally, fetal gender reporting can be selected. Our test combines the latest Next Generation Sequencing (NGS) technology with expert medical reporting.

- NIPT is a screening test based on the analysis of a maternal blood sample without the risks of invasive prenatal testing
- Highly accurate results within 5 business days
- Comprehensive reporting by our expert medical team
- Test from the 10th gestational week**
- 7–10 ml of blood from the mother required
- CAP and CLIA accreditation with fully validated workflows for sample analysis
- Analysis of twins (monozygotic and dizygotic) is also possible***

* Sample preparation and analysis software are CE-IVD marked
** Please note that in Germany, fetal gender may only be disclosed to the pregnant woman after the end of the 12th gestational week post-conception and with her consent (§ 15 para. 1 of the Genetic Diagnostics Act). Please ensure that you comply with your local laws regarding this matter.
*** Gonosomal aneuploidies cannot be detected for twin pregnancies

Expertise You Can Trust

Conventional prenatal testing for fetal chromosomal abnormality involves either chorionic villus sampling or amniocentesis. These procedures are highly invasive and carry an elevated risk of miscarriage. Despite this risk they are standard practice in most of the world because of their high levels of accuracy and the range of abnormalities they can detect.

With CentoNIPT, CENTOGENE now offers non-invasive prenatal testing that provides **fast and accurate screening for the most common prenatal chromosomal abnormalities.**

CentoNIPT is performed on a single maternal blood sample and combines the latest NGS technology with the highest quality medical reporting. It provides unparalleled accuracy and detection compared to other non-invasive testing methods – ultrasonography or nuchal translucency testing.

Our medical expertise is ideally suited to provide you and your patients with reliable, well supported interpretations of results.

Fetal Chromosomal Abnormalities

Approximately 1% of all babies will be born with a chromosomal abnormality which can cause physical disability and/or mental retardation. Roughly 70% of syndromic chromosomal abnormalities are due to Trisomies 21, 18, or 13 and 10% due to Turner syndrome (Monosomy X). The risk of Trisomy increases significantly with maternal age.

Trisomies	Sensitivity	Specificity
Trisomy 21 Down syndrome	> 99.9%	99.9%
Trisomy 18 Edwards syndrome	> 99.9%	99.9%
Trisomy 13 Patau syndrome	> 99.9%	99.9%

Sex Chromosome Aneuploides & Fetal Gender	Concordance with Cytogenetic Results
XX	100.0%
XY	100.0%
XO Turner syndrome	90.5%
XXX Triple X syndrome	100.0%
XXY Klinefelter syndrome	100.0%
XYY Jacobs syndrome	91.7%

Results and Limitations

CentoNIPT is a screening test which can detect a high risk for chromosomal aneuploidies (Trisomies 21, 18, 13) in singleton and twin pregnancies from the 10th gestational week. Fetal gender can be optionally determined by the test for singleton pregnancies; for twin gestations only the presence of Y chromosome can be determined; hence, fetal gender cannot be assigned to a specific twin. Sex chromosome aneuploidies cannot be detected for twin pregnancies. Although CentoNIPT is a high accuracy screening test for the chromosomal aneuploidies specified above, it cannot completely exclude the risk for these aneuploidies, other chromosomal abnormalities or birth defects.

Do you already have a starter set for CentoNIPT®?

Prepare the maternal sample using your individual starter set for CentoNIPT®

Order a test on CentoPortal® using the NI code from your CentoNIPT blood collection tube

Package and ship the sample in your starter set for CentoNIPT® – **for free**

Sample processing and results within 5 business days

Download your report

Do you have any questions? **Please contact us.**

The CENTOGENE Advantage

CENTOGENE offers a comprehensive package starting with NIPT for most common chromosome aneuploidies to prenatal whole exome / whole genome sequencing. After birth, we offer biomarker testing and our whole genetic test portfolio including specialized genetic analysis for critically ill newborns on ICU.

High Sensitivity & Specificity

CentoNIPT combines NGS with integrated measurement of fetal fraction, even for fetal fractions less than 4 %. This results in the lowest technical failure rate and eliminates unnecessary invasive testing as follow-up of NIPT.

Fast & Accurate Results

Our optimized workflows enable comprehensive, high-quality medical reports with validated results within 5 business days.

For More Information
centogene.com

For Ordering
centoportal.com

CENTOGENE GmbH
Am Strande 7
18055 Rostock
Germany

CENTOGENE GmbH is a subsidiary of CENTOGENE N.V.

Global Partner Support
customer.support@centogene.com
+49 381 80 113-416

Note: CentoNIPT is unavailable in the U.S.

Rostock - CLIA #99D2049715

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

ISO 15189 CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

MAmaterial-158_V31.0_V5eng_November2024